作者
Niklas Thon, Sabina Eigenbrod, Simone Kreth, Juergen Lutz, Joerg‐Christian Tonn, Hans Kretzschmar, Aurelia Peraud, Friedrich‐Wilhelm Kreth
发表日期
2012/1/15
期刊
Cancer
卷号
118
期号
2
页码范围
452-460
出版商
Wiley Subscription Services, Inc., A Wiley Company
简介
BACKGROUND
The favorable prognostic impact of mutations in the IDH1 gene is well documented for malignant gliomas; its influence on World Health Organization (WHO) grade II astrocytomas, however, is still under debate.
METHODS
A previously published database of 127 predominantly surgically treated patients harboring WHO grade II astrocytomas was revisited. Patients were screened for TP53 mutations (sequencing analysis), IDH1 mutations (pyrosequencing), and MGMT promoter methylation (methylation‐specific polymerase chain reaction and bisulfite sequencing). Endpoints were overall survival, progression‐free survival (PFS), time to malignant transformation, and postrecurrence survival. Radiotherapy was usually withheld until tumor progression/malignant transformation occurred.
RESULTS
IDH1 mutations, TP53 mutations, and methylated MGMT promoters were seen in 78.1%, 51.2%, and …
学术搜索中的文章
N Thon, S Eigenbrod, S Kreth, J Lutz, JC Tonn… - Cancer, 2012